August 18, 2020
In another rare move surrounding its diabetes treatment semaglutide, Novo Nordisk Pharma is skipping the next round of new drug listing in August for Rybelsus (semaglutide), Japan’s first oral GLP-1 agent, Jiho has learned. When drug makers take a pass...read more